A variant e13a3 BCR-ABL1 fusion transcript in refractory adult B-cell acute lymphoblastic leukemia achieving complete remission with CAR-Tcell therapy
Document Type
Article
Publication Date
1-1-2021
Abstract
Acute lymphoblastic leukemia (ALL) cases with e13a3 fusion transcripts are extremely rare. We report a 24-year-old male with Ph-positive (Ph+) ALL with an aberrant e13a3 fusion transcript treated with CD19-specific chimeric antigen receptor T-cell (CAR-T) therapy. He developed refractory disease postchemotherapy induction, andreceived allogeneic hematopoietic stem cell transplantation (allo-HSCT) after salvage with imatinib in combination with chemotherapy regimen. Unfortunately, the patient relapsed after +90 days post-transplant. He was consented to CAR-T therapy trial and achieved complete remission, highlighting the efficacy of CAR-T treatment in relapsed-refractory B-ALL irrespective of the underlying genetic drivers in leukemia cells . (C) 2020 Elsevier Inc. All rights reserved.
Keywords
Philadelphia-positive, ALL, e13a3, CART therapy, Relapsed/refractory
Divisions
InstituteofBiologicalSciences
Publication Title
Cancer Genetics
Volume
250
Publisher
Elsevier Science Inc
Publisher Location
STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA